AR066171A1 - Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. - Google Patents

Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.

Info

Publication number
AR066171A1
AR066171A1 ARP080104193A ARP080104193A AR066171A1 AR 066171 A1 AR066171 A1 AR 066171A1 AR P080104193 A ARP080104193 A AR P080104193A AR P080104193 A ARP080104193 A AR P080104193A AR 066171 A1 AR066171 A1 AR 066171A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
atom
hydrogen atom
alkoxy
Prior art date
Application number
ARP080104193A
Other languages
English (en)
Spanish (es)
Inventor
Sandrine Hilairet
Jerome Arigon
Claude Bernhart
Pierre Casellas
Samir Jegham
Monsif Bouaboula
Romain Combet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR066171A1 publication Critical patent/AR066171A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP080104193A 2007-09-28 2008-09-26 Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. AR066171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR066171A1 true AR066171A1 (es) 2009-07-29

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104193A AR066171A1 (es) 2007-09-28 2008-09-26 Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.

Country Status (19)

Country Link
US (1) US20100222319A1 (https=)
EP (1) EP2205566A2 (https=)
JP (1) JP2010540504A (https=)
KR (1) KR20100065165A (https=)
CN (1) CN101808996A (https=)
AR (1) AR066171A1 (https=)
AU (1) AU2008334457A1 (https=)
BR (1) BRPI0817973A2 (https=)
CA (1) CA2700559A1 (https=)
CL (1) CL2008002893A1 (https=)
FR (1) FR2921657A1 (https=)
IL (1) IL204663A0 (https=)
MX (1) MX2010003445A (https=)
PA (1) PA8797301A1 (https=)
PE (1) PE20091033A1 (https=)
RU (1) RU2010116765A (https=)
TW (1) TW200918056A (https=)
UY (1) UY31367A1 (https=)
WO (1) WO2009074749A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
JP7092356B2 (ja) * 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
AU2020378067A1 (en) * 2019-11-06 2022-05-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン,インコーポレーテッド Nampt阻害剤とその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
CZ20012185A3 (cs) * 1998-12-16 2001-10-17 Bayer Aktiengesellschaft Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Also Published As

Publication number Publication date
AU2008334457A1 (en) 2009-06-18
WO2009074749A2 (fr) 2009-06-18
WO2009074749A3 (fr) 2009-08-20
CN101808996A (zh) 2010-08-18
RU2010116765A (ru) 2011-11-27
PA8797301A1 (es) 2009-05-15
FR2921657A1 (fr) 2009-04-03
MX2010003445A (es) 2010-04-27
CA2700559A1 (fr) 2009-06-18
EP2205566A2 (fr) 2010-07-14
PE20091033A1 (es) 2009-08-17
US20100222319A1 (en) 2010-09-02
UY31367A1 (es) 2009-04-30
CL2008002893A1 (es) 2009-10-16
KR20100065165A (ko) 2010-06-15
IL204663A0 (en) 2010-11-30
JP2010540504A (ja) 2010-12-24
BRPI0817973A2 (pt) 2019-04-09
TW200918056A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
AR066171A1 (es) Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.
AR075920A1 (es) Derivados de nicotinamida su preparacion y su aplicacion en terapeutica
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
ECSP099269A (es) Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
CO6362007A2 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
AR066524A1 (es) Azetidinas, composiciones farmaceuticas que las comprenden y uso como antagonistas de ep2
AR066955A1 (es) Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica
AR082912A1 (es) Metodo para producir compuestos de piridazinona y un intermediario de sintesis
AR068833A1 (es) Insecticidas de pirimidinil aril hidrazonas
ES2667276T3 (es) Derivados de sulfonilindol y método para prepararlos
CO5650235A2 (es) Derivados de imidazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure